Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KRMD
KRMD logo

KRMD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
4.380
Open
4.330
VWAP
4.34
Vol
26.86K
Mkt Cap
200.32M
Low
4.280
Amount
116.48K
EV/EBITDA(TTM)
--
Total Shares
46.37M
EV
191.65M
EV/OCF(TTM)
414.47
P/S(TTM)
4.85
KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.
Show More

Events Timeline

(ET)
2026-03-12
16:40:00
KORU Medical Reports Q4 Revenue of $10.9M
select
2026-03-12
16:40:00
Sees FY26 Gross Margin Between 61%-63%
select
2026-03-12
16:20:00
Koru Medical Systems President Linda Tharby to Retire in 2026
select
2026-01-29 (ET)
2026-01-29
16:20:00
KORU Medical Receives FDA Clearance for FreedomEDGE Infusion System
select
2026-01-12 (ET)
2026-01-12
08:10:00
Koru Medical FY25 Revenue Estimated at $41.1M
select
2025-12-30 (ET)
2025-12-30
16:20:00
Koru Medical Submits 510(k) Application for FreedomEDGE System to FDA
select

News

NASDAQ.COM
9.5
03-20NASDAQ.COM
Phreesia Shares Surge 5.1% Driven by Investor Optimism
  • Significant Price Increase: Phreesia's stock surged 5.1% in the last trading session to close at $11.77, with trading volume significantly exceeding normal levels, indicating heightened market confidence in its future performance.
  • Investor Confidence Boost: Pale Fire Capital SE purchased 1,602,505 shares of Phreesia between March 17 and 19 for approximately $18.3 million, increasing its total holdings to 7,648,829 shares, which further bolstered market optimism about the company.
  • Strong Earnings Expectations: Phreesia is expected to report quarterly earnings of $0.09 per share, reflecting a year-over-year increase of 181.8%, with revenues projected at $126.37 million, up 15.2% from the previous year, showcasing the company's growth potential.
  • Market Focus: Although the consensus EPS estimate has remained unchanged over the past 30 days, research indicates a strong correlation between earnings estimate revisions and stock price movements, prompting investors to closely monitor Phreesia's future performance.
Newsfilter
8.5
03-13Newsfilter
KORU Medical Systems Secures EU Certification for Freedom60 Infusion Pump
  • EU Certification Milestone: KORU Medical Systems' Freedom60® Infusion Pump has achieved certification under the EU Medical Devices Regulation, marking a significant step towards commercialization in the EU market, which is expected to enhance the company's competitive position in Europe.
  • Enhanced Product Flexibility: The Freedom60 and FreedomEDGE® infusion systems support both 50 mL and 20 mL prefilled syringes, providing clinicians and patients with greater dosing flexibility, thereby improving patient treatment experiences and adherence.
  • Optimized Patient Experience: The increasing adoption of prefilled syringes simplifies the subcutaneous immunoglobulin (SCIg) therapy process by reducing medication handling steps, decreasing overall treatment burden, and enhancing patient confidence and independence in home therapy.
  • Market Demand Response: CEO Linda Tharby emphasized that as prefilled syringes become more widely adopted, patients are increasingly seeking simplified treatment solutions, and the Freedom60 and FreedomEDGE systems are designed to meet this need, aiming to improve patients' quality of life.
seekingalpha
9.5
03-13seekingalpha
KORU Medical Systems Q4 2025 Earnings Call Highlights
  • CEO Transition Plan: KORU Medical Systems' CEO Linda Tharby announced her retirement effective June 30, with Adam Kalbermatten set to become President on March 15 and CEO on July 1, ensuring continuity and stability in the company's strategic direction.
  • Significant Revenue Growth: The company reported Q4 2025 revenue of $10.9 million, reflecting a 23% year-over-year increase, marking three consecutive quarters of over 20% revenue growth, with full-year revenue reaching $41.1 million, a 22% rise from 2024, indicating strong market demand and execution.
  • International Market Expansion: The International Core business grew 71% in Q4 and 80% for the full year, with Tharby highlighting an increase in market share in Europe from 10% to 20%, and the expectation of adding 1 to 2 new markets each quarter, further driving revenue growth.
  • Optimistic 2026 Outlook: The company anticipates 2026 revenue guidance of $47.5 million to $50 million, representing 15% to 22% growth, with plans for positive adjusted EBITDA and cash flow, reflecting confidence in future market opportunities and strategic positioning.
Newsfilter
8.5
01-29Newsfilter
KORU Medical Receives FDA Clearance for RYSTIGGO Infusion System
  • FDA Approval: KORU Medical has received FDA clearance for the FreedomEDGE® infusion system to deliver RYSTIGGO® therapy to patients with generalized myasthenia gravis, reinforcing the company's leadership in the large-volume subcutaneous infusion market.
  • Increased Treatment Flexibility: The approval allows healthcare professionals to provide flexible treatment options in clinical settings, which is expected to significantly enhance patient access to care and improve quality of life.
  • Significant Market Potential: RYSTIGGO®, a novel biologic administered weekly at 3mL-6mL over six weeks, with subsequent cycles based on clinical evaluation, demonstrates vast potential in treating chronic autoimmune disorders.
  • Strategic Expansion Plans: KORU Medical aims to extend the Freedom platform to more drug therapies and patient populations, further enhancing its market competitiveness and driving future growth and innovation.
Newsfilter
3.5
2025-12-30Newsfilter
KORU Medical Submits 510(k) for FreedomEDGE® System to Administer PHESGO®
  • Market Expansion Milestone: KORU Medical's submission of a 510(k) application aims to utilize the FreedomEDGE® infusion system for subcutaneous administration of PHESGO®, marking a significant step in the company's strategy to penetrate the oncology infusion market, which is expected to enhance market share and meet rising demand.
  • Technological Innovation: The system is designed to support large-volume subcutaneous drug delivery, streamlining clinical workflows and is anticipated to significantly improve nursing satisfaction while reducing patient treatment time, thereby enhancing overall treatment efficiency.
  • Alignment with Industry Trends: As cancer therapies shift from intravenous to subcutaneous delivery, KORU Medical's technological advancements not only align with this trend but also position the company to potentially lead in the future drug delivery device market.
  • Future Growth Potential: KORU Medical anticipates market entry upon FDA approval, which will lay the groundwork for long-term growth in the oncology sector and further solidify its leadership in patient-centric solutions.
NASDAQ.COM
3.5
2025-12-19NASDAQ.COM
Revvity Enhances AI-Powered Scientific Research with Signals Xynthetica
  • Introduction of Signals Xynthetica: Revvity, Inc. has launched Signals Xynthetica, an AI-augmented design platform aimed at enhancing molecular and materials discovery, integrating advanced design capabilities with experimental data in a Models-as-a-Service (MaaS) framework.

  • Addressing R&D Bottlenecks: The platform seeks to bridge the gap between computational models and experimental workflows, promoting a continuous learning loop that enhances predictive insights and aligns AI predictions with laboratory practices.

  • Strategic Evolution: Revvity is transitioning from providing standalone scientific tools to becoming a platform-centric technology partner, focusing on AI-driven insights and seamless integration of scientific data across various applications, including drug discovery and clinical laboratories.

  • Market Position and Future Prospects: While Revvity's stock performance has been modest compared to industry peers, the introduction of Signals Xynthetica and other AI initiatives positions the company for potential growth as demand for integrated predictive tools in scientific research increases.

Wall Street analysts forecast KRMD stock price to rise
5 Analyst Rating
Wall Street analysts forecast KRMD stock price to rise
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
4.00
Averages
6.25
High
8.00
Current: 0.000
sliders
Low
4.00
Averages
6.25
High
8.00
B. Riley
B. Riley
Buy
maintain
$7 -> $8
AI Analysis
2026-03-13
Reason
B. Riley
B. Riley
Price Target
$7 -> $8
AI Analysis
2026-03-13
maintain
Buy
Reason
B. Riley raised the firm's price target on Koru Medical to $8 from $7 and keeps a Buy rating on the shares. Following the Q4 earnings report, B. Riley is "encouraged" by the continued execution across all three of its strategic pillars, the analyst tells investors in a research note.
Lake Street
Buy
upgrade
$6 -> $8
2025-12-22
Reason
Lake Street
Price Target
$6 -> $8
2025-12-22
upgrade
Buy
Reason
Lake Street raised the firm's price target on Koru Medical to $8 from $6 and keeps a Buy rating on the shares. The firm, which thinks a 510K submission for the oncology indication prior to year-end is "a meaningful catalyst, expects 2026 to be another year of growth acceleration and improving leverage, supporting revenue upside and multiple expansion, the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for KRMD
Unlock Now

Valuation Metrics

The current forward P/E ratio for KORU Medical Systems Inc (KRMD.O) is 188.68, compared to its 5-year average forward P/E of -32.62. For a more detailed relative valuation and DCF analysis to assess KORU Medical Systems Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-32.62
Current PE
188.68
Overvalued PE
64.49
Undervalued PE
-129.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
12.37
Current EV/EBITDA
-61.28
Overvalued EV/EBITDA
168.44
Undervalued EV/EBITDA
-143.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.51
Current PS
3.52
Overvalued PS
5.80
Undervalued PS
3.22

Financials

AI Analysis
Annual
Quarterly

Whales Holding KRMD

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is KORU Medical Systems Inc (KRMD) stock price today?

The current price of KRMD is 4.35 USD — it has increased 0.69

What is KORU Medical Systems Inc (KRMD)'s business?

KORU Medical Systems, Inc. is a medical technology company. The Company is focused on developing, manufacturing, and commercializing patient-centric large volume subcutaneous infusion solutions primarily for the subcutaneous drug delivery market. The Company is focused on its mechanical infusion products, the FREEDOM Infusion Systems (FREEDOM System), which include the FREEDOM60 Syringe Driver, the FreedomEdge Syringe Driver, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. The Company’s infusion devices work together as a system to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD) and chronic inflammatory demyelinating polyneuropathy (CIDP). The FREEDOM System operates at a lower pressure than an electrical, volumetric pump and maintains a balance between what a patient’s subcutaneous tissues can tolerate and what the system delivers.

What is the price predicton of KRMD Stock?

Wall Street analysts forecast KRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRMD is6.25 USD with a low forecast of 4.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is KORU Medical Systems Inc (KRMD)'s revenue for the last quarter?

KORU Medical Systems Inc revenue for the last quarter amounts to 10.89M USD, increased 23.27

What is KORU Medical Systems Inc (KRMD)'s earnings per share (EPS) for the last quarter?

KORU Medical Systems Inc. EPS for the last quarter amounts to -0.01 USD, decreased -66.67

How many employees does KORU Medical Systems Inc (KRMD). have?

KORU Medical Systems Inc (KRMD) has 73 emplpoyees as of April 01 2026.

What is KORU Medical Systems Inc (KRMD) market cap?

Today KRMD has the market capitalization of 200.32M USD.